Buy Dr Lal Pathlabs Ltd for the Target Rs 1,740 by Emkay Global Financial Services Ltd
We hosted the senior management (CEO, CFO) of Dr Lal Pathlabs (DLPL) for a non-deal road show (NDR), meeting long only funds across multiple cities in the US.
Key takeaways:
1) Despite being the industry leader, DLPL is likely to grow at 1.3-1.4x the industry rate over the next 4-5 years, driven by investments in network infrastructure and revitalization of its sales channels.
2) While North and East will continue to drive majority of organic growth, inorganic expansion in the West and South should accelerate regional revenue diversification and improve geographic parity.
3) DLPL has identified premium wellness (Sovaaka, integrated diagnostics) and international expansion (Southeast Asia, Africa, and CIS regions) as medium- to long-term growth drivers, in addition to its existing moats of specialized testing capabilities, extensive network reach, and brand goodwill.
4) While competitive intensity remains elevated, the management believes the pricing-led disruption is largely behind, with both online and unorganized competitors exhausting the profits and funding accumulated during the Covid period.
5) DLPL has not taken any price hikes since Feb’23 and expects tariff-related realizations to contribute only 1-1.5% CAGR to overall revenue growth, in line with the last decade. We maintain BUY with an unchanged Mar-27E TP of Rs1,740 (DCF-based), implying FY28E PER of 43x and 37x EV/OCF.
From network build-up to next-gen diagnostics
Following a hiatus in network expansion during Covid, DLPL accelerated its network rollout by commissioning 30 labs and 2,000+ collection centers (CCs) over the last two years—a ~1.5x jump vs its run rate of 600-700 CCs during FY20-24. These investments, along with reinvigoration of channel partners, have spurred sample volume growth (9%/11% YoY in FY25/26). Geographic expansion remains disciplined, with North and East India anchoring near-term organic volume and tier 3+ markets contributing 39% to revenue. Alongside network densification, DLPL is strengthening its specialized diagnostics capabilities through a growing genomics pipeline spanning cytogenetics, BRCA/MICA screening, and molecular diagnostics. The addition of Illumina's NovaSeq X series in Jul-25 marks a tangible step-up in sequencing throughput and AI-powered clinical testing.
Industry tailwinds to benefit market leader
Given its market share, DLPL's wellness portfolio (Swasthfit) is well placed to capture the growing awareness of preventive testing post-Covid (FY20-26 CAGR of 24%). Complementing this is Sovaaka, DLPL's premium concierge wellness brand, which targets affluent urban patients with an immersive, hospital-independent diagnostic experience. While still at an early-stage of adoption, Sovaaka positions the company at the premium end of a wellness-spend market that urban India is now beginning to formalize.
For More Emkay Global Financial Services Ltd Disclaimer http://www.emkayglobal.com/Uploads/disclaimer.pdf & SEBI Registration number is INH000000354
